Cargando…

A Randomized Double‐Blind Placebo‐Controlled First‐In‐Human Phase 1 Trial of TransCon PTH in Healthy Adults

TransCon PTH is a sustained‐release, essentially inactive prodrug transiently bound to an inert carrier, designed to release PTH(1‐34), and in development for hypoparathyroidism (HP). This phase 1, randomized, placebo‐controlled, single and multiple ascending dose (SAD and MAD, respectively) trial e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karpf, David B, Pihl, Susanne, Mourya, Sanchita, Mortensen, Eva, Kovoor, Eshwari, Markova, Denka, Leff, Jonathan A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328939/ https://www.ncbi.nlm.nih.gov/pubmed/32212275 http://dx.doi.org/10.1002/jbmr.4016

Ejemplares similares

PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism
por: Khan, Aliya A, et al.
Publicado: (2021)

SAT-LB72 Design of the PaTH Forward Phase 2 Trial of TransCon PTH, a Long-Acting PTH, in Patients With Hypoparathyroidism
por: Khan, Aliya Aziz, et al.
Publicado: (2020)

TransCon PTH as a Hormone Replacement Therapy for Patients with Hypoparathyroidism: 6-Month Update from the PaTH Forward Open-Label Extension
por: Rubin, Mishaela R, et al.
Publicado: (2021)

OR21-1 The PaTH Forward Trial: Efficacy and Safety of TransCon PTH Through Week 84 for Adults With Hypoparathyroidism
por: Ahmed, Intekhab, et al.
Publicado: (2022)

The rationale and design of TransCon Growth Hormone for the treatment of growth hormone deficiency
por: Sprogøe, Kennett, et al.
Publicado: (2017)

Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26‐Week Results From the Phase 3 PaTHway Trial
por: Khan, Aliya A, et al.
Publicado: (2022)

A phase 2 trial of long-acting TransCon growth hormone in adult GH deficiency
por: Höybye, Charlotte, et al.
Publicado: (2017)

Once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACcomplisH): a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-escalation trial
por: Savarirayan, Ravi, et al.
Publicado: (2023)

OR29-5 Phase 3 PaTHway Trial: Participants Treated With TransCon PTH Achieved Independence From Conventional Therapy While Maintaining Normal Serum Calcium
por: Khan, Aliya
Publicado: (2022)

THU156 Significantly Improved Annual Height Velocity With Once-Weekly TransCon CNP In Children With Achondroplasia: The ACcomplisH Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial
por: Savarirayan, Ravi, et al.
Publicado: (2023)

OR17-4 Transcon Growth Hormone In The Treatment Of Pediatric Growth Hormone Deficiency: Results Of The Phase 3 Height Trial
por: Thornton, Paul, et al.
Publicado: (2019)

OR10-05 Phase 3 FliGHt Trial: Experience of Switching from Daily Growth Hormone Therapy to Once-Weekly TransCon HGH in Children with Growth Hormone Deficiency
por: Maniatis, Aristides K, et al.
Publicado: (2020)

Psychometric validation of the Hypoparathyroidism Patient Experience Scales (HPES)
por: Brod, Meryl, et al.
Publicado: (2021)

OP Transcon 2018 Compilation
Publicado: (2019)

PP Transcon 2018 Compilation
Publicado: (2019)

Design of the ForesiGHt Trial: A Multicenter, Randomized, Placebo- and Active-Controlled Trial to Compare Once-Weekly TransCon hGH (lonapegsomatropin) to Placebo and Daily Somatropin in Adults With Growth Hormone Deficiency (GHD)
por: Fleseriu, Maria, et al.
Publicado: (2021)

Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamics results of a long‐acting C‐type natriuretic peptide prodrug, TransCon CNP
por: Breinholt, Vibeke Miller, et al.
Publicado: (2022)

TRANSCON 2022 B: Poster Papers
Publicado: (2023)

TRANSCON 2022 B: Oral Abstracts
Publicado: (2023)

Efficacy and Safety of up to 2 Years of Treatment With TransCon hGH (Lonapegsomatropin) in Treatment-Naïve and Treatment-Experienced Children With Growth Hormone Deficiency
por: Maniatis, Aristides K, et al.
Publicado: (2021)

OR23-05 Log-term Efficacy And Safety Of Transcon PTH In Adults With Hypoparathyroidism: 52-week Results From The Open-label Extension Of The Phase 3 Pathway Trial
por: Clarke, Bart, et al.
Publicado: (2023)

Intratumoral delivery of TransCon(™) TLR7/8 Agonist promotes sustained anti-tumor activity and local immune cell activation while minimizing systemic cytokine induction
por: Zúñiga, Luis Alejandro, et al.
Publicado: (2022)

38(th) ISBTI Annual Conference, TRANSCON 2013, Surat
Publicado: (2014)

SAT-LB16 Maintenance of Favorable Treatment Effect of Once-Weekly TransCon hGH for Children With Growth Hormone Deficiency: Interim Analysis From the Enlighten Long-Term Extension Trial
por: Maniatis, Aristides K, et al.
Publicado: (2020)

39(th) ISBTI Annual Conference, TRANSCON 2014, Surat Patiala
Publicado: (2015)

40(th) ISBTI Annual Conference, TRANSCON 2015, New Delhi
Publicado: (2016)

Randomized, Double‐Blind, Placebo‐Controlled Trial of Intraarticular Trans‐Capsaicin for Pain Associated With Osteoarthritis of the Knee
por: Stevens, Randall M., et al.
Publicado: (2019)

Randomised, double-blind, placebo-controlled crossover study of single-dose guanfacine in unilateral neglect following stroke
por: Dalmaijer, Edwin S, et al.
Publicado: (2018)

TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer
por: Rosen, David B, et al.
Publicado: (2022)

Optimization of PTH/PTHrP Hybrid Peptides to Derive a Long‐Acting PTH Analog (LA‐PTH)
por: Noda, Hiroshi, et al.
Publicado: (2020)

TRANSCON 2020 45(th) Annual Conference ISBTI 27(th) & 28(th) Feb 2021
Publicado: (2021)

Antiplatelet effects of citalopram in patients with ischaemic stroke: A randomized, placebo-controlled, double-blind study
por: Kraglund, Kristian Lundsgaard, et al.
Publicado: (2019)

Decrease in the expression of the type 1 PTH/PTHrP receptor (PTH1R) on chondrocytes in animals with osteoarthritis
por: Becher, Christoph, et al.
Publicado: (2010)

A double-blind placebo needle for acupuncture research
por: Takakura, Nobuari, et al.
Publicado: (2007)

Inverse correlation of intact PTH, oxidized PTH as well as non-oxidized PTH with 25-hydroxyvitamin D3 in kidney transplant recipients
por: Zuo, Jiao, et al.
Publicado: (2023)

Disruption of PTH Receptor 1 in T Cells Protects against PTH-Induced Bone Loss
por: Tawfeek, Hesham, et al.
Publicado: (2010)

The whole-PTH/intact-PTH ratio is a useful predictor of severity of secondary hyperparathyroidism
por: Tanaka, Motoko, et al.
Publicado: (2008)

OR07-01 Identification of the First Case of Acquired Autoimmune Parathyroid Hormone (PTH) Resistance Due to PTH1 Receptor (PTH1R) Autoantibodies
por: Mandl, Adel, et al.
Publicado: (2020)

A Single Administration of AZP-3601, a Novel, Long-Acting PTH Analog, Induces a Significant and Sustained Calcemic Response: Preliminary Data From a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study
por: Allas, Soraya, et al.
Publicado: (2021)

Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study
por: Cavanna, Federico, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ttb7nioglkrb4hheha7a1s83d2